A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

This early-phase study tests a new oral drug called NTQ2494 in patients with a blood cancer called acute myeloid leukemia (AML) that has returned or stopped responding to prior treatment. The study focuses on safety and finding the right dose. **You may be eligible if...** - You are 18 or older - You have relapsed or treatment-resistant AML - You are in reasonably good overall health and can care for yourself - You have a life expectancy of at least 3 months - Your bone marrow and major organs are functioning adequately **You may NOT be eligible if...** - You received cancer treatment, immunotherapy, or radiation in the past 2 weeks (or within 5 drug half-lives) - You participated in another clinical trial in the past 4 weeks - You had major surgery in the past 4 weeks - You have active hepatitis B or C, HIV, or active serious infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.